Stay up-to-date with the latest developments in gene and cell therapy by subscribing to our newsletter.
Featured:
Jun 04 | Sarepta Therapeutics Receives FDA Platform Technology Designation for its rAAVrh74 Viral Vector read more »
Jun 04 | Gilead Prepares Outpatient BCMA CAR T Entry to Challenge J&J Multiple Myeloma Market read more »
Jun 03 | New CBER Director Pledges Swift Action, Flexibility for Rare Disease Treatments read more »
News:
Jun 05 | Regenxbio Reports Positive Functional Outcomes for RGX-202 AAV Gene Therapy in Duchenne read more »
Jun 05 | Ocugen Announces Key Licensing Agreement for OCU400 in South Korea: A Novel AAV Gene Therapy for RP read more »
Jun 04 | Elpis Biopharmaceuticals Collaborates with Singapore General Hospital to Advance Next-Generation CAR-T Therapies for Blood Cancers read more »
Jun 03 | Beam Therapeutics’ BEAM-101 Receives FDA Orphan Drug Designation for Sickle Cell Disease read more »
Jun 02 | Diakonos Oncology’s mRNA-Loaded DOC1021 Shows Promising Phase I Glioblastoma Results, Advances to Phase II read more »
Jun 02 | uniQure Nears BLA Submission for Groundbreaking AAV-Based Gene Therapy AMT-130 for Huntington’s Disease read more »
May 31 | Moderna’s Next-Gen mRNA COVID-19 Vaccine, mNexspike, Receives Targeted FDA Approval read more »
May 30 | Myeloid Therapeutics Unveils Pioneering In Vivo mRNA CAR Therapies read more »
May 30 | Novel Universal CAR-T Cell Therapy Shows High Remission Rates in Aggressive Blood Cancers read more »
May 26 | World Health Assembly Unanimously Adopts Landmark Resolution Elevating Rare Diseases as a Global Health Priority read more »
Articles:
Jun 05 | A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence read more »
Jun 04 | A phase 1 clinical trial shows safe, sustained, AAV-mediated expression of IL-1Ra in the human osteoarthritic knee joint read more »
Jun 04 | Periostin Exon 17 Skipping Enhances the Efficacy of Local Adeno-Associated Viral-Microdystrophin Administration in a Fibrotic Model of Duchenne Muscular Dystrophy read more »
Jun 04 | AAV8-LDLR Gene Therapy in Ldlr-KO and Homozygous Ldlr p.W483X Mice read more »
Jun 04 | Recombinant Adeno-Associated Virus Integration Profiles in Nonhuman Primates and Gene Therapy Participants after Treatment with Valoctocogene Roxaparvovec read more »
Jun 03 | Structural basis of liver de-targeting and neuronal tropism of CNS-targeted AAV capsids read more »
Jun 03 | Senescence and inflammation are unintended adverse consequences of CRISPR-Cas9/AAV6-mediated gene editing in hematopoietic stem cells read more »
Jun 03 | Powering new therapeutics with precision mitochondrial editing read more »
Jun 03 | Resurrecting a miniature Cas9 ancestor for genome and epigenome editing read more »
May 31 | Precision multiplexed base editing in human cells using Cas12a-derived base editors read more »
May 30 | Phase 1/2 Trial of Anti-CD7 Allogeneic WU-CART-007 in patients with Relapsed/Refractory T-cell Malignancies read more »
May 29 | Poly(carboxybetaine) lipids enhance mRNA therapeutics efficacy and reduce their immunogenicity read more »
May 28 | Neuron-targeted caveolin-1 overexpression attenuates cognitive loss and pathological transcriptome changes in symptomatic Alzheimer’s disease models read more »
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
